AccuVAC-PT001

AccuVAC-PT001 is an investigational **protein-based COVID-19 vaccine** developed by Defence Therapeutics. It consists of the SARS-CoV-2 spike protein chemically modified with the company's proprietary Accum moiety and is intended to induce neutralizing antibody responses, particularly against receptor-binding domain epitopes involved in ACE2 interaction. The product is administered as an injectable biologic vaccine for the prevention of COVID-19 infection, and preclinical reports described cross-reactive immune responses against multiple SARS-CoV-2 variants including Delta, Californian, South African, Brazilian, and UK strains. Based on the provided context, the program had completed rabbit toxicology studies and was being prepared for Phase 1 clinical testing planned for 2022.